[Remote afterloading high dose rate intracavitary radiotherapy for head and neck cancer (author's transl)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Ozeki.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Overall 2-year actuarial survival rates were 77 and 81 per cent in a high and a low dose rate group, respectively. In the high dose rate group 60 patients were controlled, 8 developed rectal bleeding, and 7 recurred. In the low dose rate group 54 were controlled, one developed rectal bleeding, and 9 recurred. Optimum TDF was 125 in both groups.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.